Expert Ratings for Eledon Pharma
Portfolio Pulse from Benzinga Insights
Eledon Pharma (NASDAQ:ELDN) received 4 analyst ratings in the last quarter, with 2 bullish and 2 somewhat bullish, and no indifferent, somewhat bearish, or bearish ratings. The average 12-month price target for ELDN is $11.25, with a high of $13.00 and a low of $9.00. This target is a 55.0% decrease from the previous target of $25.00. Analysts typically review stocks quarterly or after major company updates, considering financial performance and company risks.
November 13, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Eledon Pharma has a positive outlook from analysts with 4 bullish ratings and a new average price target of $11.25, which is significantly lower than the previous target of $25.00.
The reduction in the average price target for ELDN suggests a recalibration of expectations, possibly due to new market information or changes in the company's outlook. While the ratings are positive, the significant decrease in the price target could lead to mixed reactions in the short term, as investors reassess the company's valuation.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100